USP8 and hepatocellular carcinoma: We further demonstrated that USP8 inhibition can overcome HCC drug resistance as shown by the observations that USP8 inhibition 1) was active against doxorubicin-resistant HCC cells and 2) significantly augmented the inhibitory effects of doxorubicin and sorafenib (Figures 2D–2F, 3C–3F).